Polaris Group Announced The Acquisition Of Genovior Biotech, Initiating Dual-Engine Growth
Acquiring Company
Polaris Group
Acquired Company
Genovior Biotech Corporation
San Diego
TaipeiPharmaceutical ManufacturingPharmaceutical ManufacturingDescription
Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%. Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group. This significant decision not only allows Polaris Group to expand the product pipeline beyond its novel cancer metabolism therapy but also marks its entry into the highly promising realm of peptide drugs, such as the widely recognized Semaglutide-related products. These two highly prospective product lines will serve as the dual engines propelling Polaris Group's future growth.
Quick answer
Polaris Group is acquiring Genovior Biotech Corporation, announced December 22, 2023. Polaris Group is based in San Diego, California, United States.
- How much did Polaris Group pay for Genovior Biotech Corporation?
- The deal value was not disclosed.
- What does Polaris Group do?
- Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans.
- Where are Polaris Group and Genovior Biotech Corporation based?
- Polaris Group is based in San Diego, California, United States. Genovior Biotech Corporation is based in Taipei, Taipei City, Taiwan.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical Manufacturing and Pharmaceutical Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Merck Animal Health to Acquire Elanco’s Aqua Business (February 5, 2024)
- ClinChoice Acquires CSI, Expanding its Global Footprint into Southeast Asia (January 12, 2024)
- Astellas Completes Acquisition Of Propella Therapeutics (December 21, 2023)
- Astellas To Acquire Propella Therapeutics (November 15, 2023)
- Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic (January 31, 2024)
- InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain (January 31, 2024)
Who to call at Polaris Group, and when
When Polaris Group changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Polaris Group raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Polaris Group, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Polaris Group. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Polaris Group makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Genovior Biotech Corporation?
Genovior Biotech Corporation was acquired by Polaris Group, based in San Diego. The deal was reported on December 22, 2023. Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris Group is privately held and operates in Pharmaceutical Manufacturing.
When did Polaris Group acquire Genovior Biotech Corporation?
Polaris Group's acquisition of Genovior Biotech Corporation was reported on December 22, 2023. Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%. Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Genovior Biotech Corporation do?
Genovior Biotech Corporation operates several aseptic GMP production facilities capable of producing clinical or commercial materials based on CDMO. It is privately held, operating in Pharmaceutical Manufacturing, and is based in Taipei.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.